Kazia Therapeutics

Kazia Therapeutics Limited (KZA) is an oncology-focused biotechnology company. KZA is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies known as Super-benzopyrans and Anti-tropomyosins. KZA is headquartered in Sydney, Australia, with an office in New Haven, Connecticut in the US.

Contact Details

Level 24, Three International Towers , 300 Barangaroo Ave SYDNEY NSW 2000

02 9472 4100

secretary@novogen.com

www.kaziatherapeutics.com

Lists and Charts

Share price

Kazia Therapeutics
Closing price for the last 90 trading days

View ASX Chart

Revenue

Rank		Company	#
894^th	-	Kazia Therapeutics	$3.39m

1330 public companies - non WA ranked by total revenue

View Full List

Company Share Transactions

Company Activity

	NEW ROLE: J Friend,	03 Nov 2022
	NEW ROLE: K Krumeich,	03 Nov 2022
	NEWS: Tagged in Where markets meet medicine; a biotech entrepreneur at the tip of the spear	14 Feb 2022
	NEW ROLE: P Leong,	24 Nov 2020
	NEW ROLE: G Hirsch,	24 Nov 2020
	NEW ROLE: G Heaton, Dir:Finance & Administration	24 Nov 2020
	NEW ROLE: Kate Hill, Company Secretary	24 Nov 2020
	NEW ROLE: Steven RS Coffey, Non-Executive Director	03 Nov 2020

Related Information

Access to our data for Kazia Therapeutics is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Kazia Therapeutics is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today